Vanda Pharmaceuticals diskutieren
Vanda Pharmaceuticals
WKN: A0JJT3 / Symbol: VNDA / Name: Vanda Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
6,90 €
2,21 %
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) had its price target raised by analysts at Cantor Fitzgerald from $11.00 to $13.00. They now have an "overweight" rating on the stock.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) had its price target raised by analysts at HC Wainwright from $18.00 to $20.00. They now have a "buy" rating on the stock.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $13.00 price target on the stock.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) had its price target lowered by analysts at Cantor Fitzgerald from $13.00 to $11.00. They now have an "overweight" rating on the stock.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Ratings data for VNDA provided by MarketBeat
Neueste Beiträge
Roth_Mkm in Insmed Inc. diskutieren